- Home
- XGN vs SGMO Comparison
XGN vs SGMO Comparison
Compare XGN & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | SGMO |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 131.2M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | XGN | SGMO |
|---|---|---|
| Price | $3.29 | $0.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $12.00 | $5.75 |
| AVG Volume (30 Days) | 734.3K | ★ 8.4M |
| Earning Date | 03-10-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,599,000.00 | $32,875,000.00 |
| Revenue This Year | $21.40 | $4.79 |
| Revenue Next Year | $14.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $2.67 | $0.35 |
| 52 Week High | $12.23 | $1.24 |
Technical Indicators
Market Signals| Indicator | XGN | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 23.70 | 46.71 |
| Support Level | $3.30 | $0.35 |
| Resistance Level | $3.69 | $0.41 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 2.99 | 19.57 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.